India-based Sun Pharmaceutical Industries Limited agreed to acquire U.S.-based immunotherapy and targeted oncology company ...

India's pharma giant Sun Pharma is to acquire Checkpoint Therapeutics (NASDAQ:CKPT)—an immunotherapy and targeted ...

Checkpoint Therapeutics is being acquired by Sun Pharmaceutical for $4.10 per share. Learn why CKPT stockholders could earn ...

The deal is in line with Sun Pharma's active push in recent years to expand its oncology and immunotherapy portfolio through ...

Sun Pharmaceutical Industries—controlled by Indian billionaire Dilip Shanghvi—has agreed to buy U.S.-based immunotherapy and ...

Sun Pharmaceutical announced the acquisition of Nasdaq-listed Checkpoint Therapeutics, an immunotherapy and oncology company.

Sun Pharma’s acquisition of Checkpoint Therapeutics includes Unloxcyt, an FDA-approved anti-PD-L1 therapy for metastatic and ...

Sun Pharma will acquire Checkpoint Therapeutics for $355 million, expected to close by Q2 2025. The deal strengthens Sun ...

Sun Pharma has acquired Checkpoint Therapeutics for $355 million, enhancing its onco-dermatology portfolio with the ...

Sun Pharmaceutical Industries Ltd. on Monday announced it will acquire US-based cancer treatment provider Checkpoint ...

Sun Pharma to acquire Checkpoint Therapeutics, expanding innovative portfolio in onco-derm therapy with FDA-approved UNLOXCYT ...

Three months after an FDA approval for cancer immunotherapy Unloxcyt, Checkpoint Therapeutics has found a buyer. | Three ...